Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients

References

• HernánMASauerBCHernández-DíazSPlattRShrierISpecifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analysesJ Clin Epidemiol201679707527237061
   PubMed Web of Science ®Google Scholar
• WeberpalsJJansenLCarrPRHoffmeisterMBrennerHBeta blockers and cancer prognosis – the role of immortal time bias: a systematic review and meta-analysisCancer Treat Rev20164711127179912
   PubMed Web of Science ®Google Scholar
• BeyersmannJGastmeierPWolkewitzMSchumacherMAn easy mathematical proof showed that time-dependent bias inevitably leads to biased effect estimationJ Clin Epidemiol200861121216122118619803
   PubMed Web of Science ®Google Scholar
• WolkewitzMAllignolAHarbarthSde AngelisGSchumacherMBeyersmannJTime-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of biasJ Clin Epidemiol201265111171118023017635
   PubMed Web of Science ®Google Scholar
• MantelNByarDPEvaluation of response-time data involving transient states: an illustration using heart-transplant dataJ Am Stat Assoc1974693458186
   Web of Science ®Google Scholar
• MiXHammillBGCurtisLHLaiECSetoguchiSUse of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation studyStat Med201635264824483627350312
   PubMed Web of Science ®Google Scholar
• SuissaSImmortal time bias in pharmaco-epidemiologyAm J Epidemiol2008167449249918056625
   PubMed Web of Science ®Google Scholar
• AndersonJRCainKCGelberRDAnalysis of survival by tumor responseJ Clin Oncol19831117107196668489
   PubMed Web of Science ®Google Scholar
• LiaoWCChienKLLinYLAdjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysisLancet Oncol201314111095110324035532
   PubMed Web of Science ®Google Scholar
• DucreuxMCuhnaASCaramellaCESMO Guidelines CommitteeCancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201526Suppl 5v56v6826314780
   PubMed Web of Science ®Google Scholar
• KhoranaAAManguPBBerlinJPotentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice GuidelineJ Clin Oncol201634212541255627247221
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPDunnJAStockenDDEuropean Study Group for Pancreatic CancerAdjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trialLancet200135892931576158511716884
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPStockenDDFriessHEuropean Study Group for Pancreatic CancerA randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancerN Engl J Med2004350121200121015028824
   PubMed Web of Science ®Google Scholar
• OettleHPostSNeuhausPAdjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trialJAMA2007297326727717227978
   PubMed Web of Science ®Google Scholar
• OettleHNeuhausPHochhausAAdjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trialJAMA2013310141473148124104372
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPStockenDDBassiCEuropean Study Group for Pancreatic CancerAdjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trialJAMA2010304101073108120823433
   PubMed Web of Science ®Google Scholar
• BakensMJvan der GeestLGvan PuttenMDutch Pancreatic Cancer GroupThe use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysisCancer Med20165102825283127671746
   PubMed Web of Science ®Google Scholar
• ValleJWPalmerDJacksonROptimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 studyJ Clin Oncol201432650451224419109
   PubMed Web of Science ®Google Scholar
• XiaBTAhmadSAAl HumaidiAHTime to initiation of adjuvant chemotherapy in pancreas cancer: a multi-institutional experienceAnn Surg Oncol20172492770277628600732
   PubMed Web of Science ®Google Scholar
• LinDYWeiLJThe robust inference for the Cox proportional hazards modelJ Am Stat Assoc19898440810741078
   Web of Science ®Google Scholar
• VaidaFXuRProportional hazards model with random effectsStat Med200019243309332411122497
   PubMed Web of Science ®Google Scholar
• GrambschPMTherneauTMProportional hazards tests and diagnostics based on weighted residualsBiometrika1994813515526
   Web of Science ®Google Scholar
• R Core TeamR: a language and environment for statistical computingViennaR Foundation for Statistical Computing2015 Available from: http://www.R-project.org/Accessed 31 July, 2018
   Google Scholar
• SchwarzerGMeta: meta-analysis with R. R package version 4.3-2 Available from: http://CRAN.R-project.org/package=metaAccessed December 2, 2015
   Google Scholar
• YoshidaKBohnJ R Package ‘tableone’. https://github.com/kaz-yos/tableoneAccessed November 30, 2016
   Google Scholar
• TherneauTMA package for survival analysis in S. version 2.38 Available from: https://CRAN.R-project.org/package=survivalAccessed September 28, 2017
   Google Scholar
• JonesMFowlerRImmortal time bias in observational studies of time-to-event outcomesJ Crit Care20163619519927546771
   PubMed Web of Science ®Google Scholar
• MiXHammillBGCurtisLHGreinerMASetoguchiSImpact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter-defibrillatorsJ Clin Epidemiol2013668 SupplS138S14423849148
   PubMed Web of Science ®Google Scholar
• ParkHSGrossCPMakarovDVYuJBImmortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapyInt J Radiat Oncol Biol Phys20128351365137322342097
   PubMed Web of Science ®Google Scholar
• DafniULandmark analysis at the 25-year landmark pointCirc Cardiovasc Qual Outcomes20114336337121586725
   PubMed Web of Science ®Google Scholar
• ‘t Lam-BoerJVan der GeestLGVerhoefCElferinkMEKoopmanMde WiltJHPalliative resection of the primary tumor is associated with improved overall survival in incurable stage IV colorectal cancer: a nationwide population-based propensity-score adjusted study in the NetherlandsInt J Cancer201613992082209427342618
   PubMed Web of Science ®Google Scholar
• YWHuStatins and the risk of pancreatic cancer in Type 2 diabetic patients: immortal time bias in survival analysis?Int J Cancer2016139123226918933
   PubMed Web of Science ®Google Scholar
• HuZHConnettJEYuanJMAndersonKERole of survivor bias in pancreatic cancer case-control studiesAnn Epidemiol2016261505626688282
   PubMed Web of Science ®Google Scholar
• MokdadAAMinterRMZhuHNeoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysisJ Clin Oncol201735551552227621388
   PubMed Web of Science ®Google Scholar
• GillBSFlickingerJCBeriwalSCaveat for immortal time bias in adjuvant therapy–related population-based analysesJ Clin Oncol20153326293126215960
   PubMed Web of Science ®Google Scholar
• LaiTYHuYWNeoadjuvant therapy in resectable pancreatic cancer: immortal time bias and its correctionJ Clin Oncol20173514162328135147
   PubMed Web of Science ®Google Scholar
• WeberpalsJJansenLvan Herk-SukelMPPImmortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosisEur J Epidemiol201732111019103128864947
   PubMed Web of Science ®Google Scholar
• Giobbie-HurderAGelberRDReganMMChallenges of guarantee-time biasJ Clin Oncol201331232963296923835712
   PubMed Web of Science ®Google Scholar
• FranklinJMSchneeweissSWhen and how can real world data analyses substitute for randomized controlled trials?Clin Pharmacol Ther2017102692493328836267
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPPalmerDHGhanehPEuropean Study Group for Pancreatic CancerComparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialLancet2017389100731011102428129987
   PubMed Web of Science ®Google Scholar
• ZacharyIBorenSASimoesEJackson-ThompsonJDavisJWHicksLInformation management in cancer registries: evaluating the needs for cancer data collection and cancer researchOnline J Public Health Inform201572e21326392844
   PubMedGoogle Scholar
• van WalravenCDavisDForsterAJWellsGATime-dependent bias was common in survival analyses published in leading clinical journalsJ Clin Epidemiol200457767268215358395
   PubMed Web of Science ®Google Scholar